CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherapeutics titled “A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain” by Eugene R. Viscusi, M.D., Director of Acute Pain Management at Jefferson Health (DOI: https://doi.org/10.1080/14737175.2022.2072731).
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.